Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Intangibles (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Intangibles for 15 consecutive years, with $6.7 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Intangibles rose 105.68% year-over-year to $6.7 million, compared with a TTM value of $6.7 million through Dec 2024, up 105.68%, and an annual FY2024 reading of $6.7 million, up 105.68% over the prior year.
  • Intangibles was $6.7 million for Q4 2024 at China Pharma Holdings, up from $4.4 million in the prior quarter.
  • Across five years, Intangibles topped out at $6.7 million in Q4 2024 and bottomed at $147841.0 in Q4 2021.
  • Average Intangibles over 5 years is $2.1 million, with a median of $1.8 million recorded in 2022.
  • The sharpest move saw Intangibles decreased 22.57% in 2020, then soared 1122.59% in 2022.
  • Year by year, Intangibles stood at $182146.0 in 2020, then fell by 18.83% to $147841.0 in 2021, then skyrocketed by 1122.59% to $1.8 million in 2022, then skyrocketed by 80.1% to $3.3 million in 2023, then soared by 105.68% to $6.7 million in 2024.
  • Business Quant data shows Intangibles for CPHI at $6.7 million in Q4 2024, $4.4 million in Q3 2024, and $4.4 million in Q2 2024.